;PMID: 11270913
;source_file_914.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..153] = [t:52..153]
;2)section:[e:157..228] = [t:157..228]
;3)section:[e:232..287] = [t:232..287]
;4)sentence:[e:291..398] = [t:291..398]
;5)sentence:[e:399..539] = [t:399..539]
;6)sentence:[e:540..813] = [t:540..813]
;7)sentence:[e:814..966] = [t:814..966]
;8)sentence:[e:967..1144] = [t:967..1144]
;9)sentence:[e:1145..1271] = [t:1145..1271]
;10)sentence:[e:1272..1502] = [t:1272..1502]
;11)sentence:[e:1503..1590] = [t:1503..1590]
;12)sentence:[e:1591..1766] = [t:1591..1766]
;13)section:[e:1770..1815] = [t:1770..1815]

;section 0 Span:0..46
;J Clin Psychopharmacol. 2001 Apr;21(2):167-74.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Clin) (NNP:[7..22] Psychopharmacol)
        (.:[22..23] .) (CD:[24..28] 2001) (CC:[29..36] Apr;21-LRB-)
        (CD:[36..37] 2) (-RRB-:[37..38] -RRB-) (CD:[38..42] :167) (::[42..43] -)
        (CD:[43..45] 74) (.:[45..46] .)))

;sentence 1 Span:52..153
;Differential effects of fluvoxamine and other antidepressants on the 
;biotransformation of melatonin.
;[76..87]:substance:"fluvoxamine"
;[98..113]:substance:"antidepressants"
;[143..152]:substance:"melatonin"
(SENT
  (NP-HLN
    (NP (JJ:[52..64] Differential) (NNS:[65..72] effects))
    (PP (IN:[73..75] of)
      (NP
        (NP (NN:[76..87] fluvoxamine))
        (CC:[88..91] and)
        (NP (JJ:[92..97] other) (NNS:[98..113] antidepressants))))
    (PP (IN:[114..116] on)
      (NP
        (NP (DT:[117..120] the) (NN:[122..139] biotransformation))
        (PP (IN:[140..142] of)
          (NP (NN:[143..152] melatonin)))))
    (.:[152..153] .)))

;section 2 Span:157..228
;Hartter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C.
(SEC
  (FRAG (NNP:[157..164] Hartter) (NNP:[165..166] S) (,:[166..167] ,)
        (NNP:[168..172] Wang) (NNP:[173..174] X) (,:[174..175] ,)
        (NNP:[176..184] Weigmann) (NNP:[185..187] H,) (NNP:[188..197] Friedberg)
        (NNP:[198..199] T) (,:[199..200] ,) (NNP:[201..206] Arand)
        (NNP:[207..209] M,) (NNP:[210..215] Oesch) (NNP:[216..217] F)
        (,:[217..218] ,) (NNP:[219..225] Hiemke) (NNP:[226..228] C.)))

;section 3 Span:232..287
;Department of Psychiatry, University of Mainz, Germany.
(SEC
  (FRAG (NNP:[232..242] Department) (IN:[243..245] of)
        (NNP:[246..256] Psychiatry) (,:[256..257] ,) (NNP:[258..268] University)
        (IN:[269..271] of) (NNP:[272..277] Mainz) (,:[277..278] ,)
        (NNP:[279..286] Germany) (.:[286..287] .)))

;sentence 4 Span:291..398
;Melatonin, the predominant product of the pineal gland, is involved in the 
;maintenance of diurnal rhythms.
;[291..300]:substance:"Melatonin"
;[318..325]:substance:"product"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[291..300] Melatonin))
      (,:[300..301] ,)
      (NP
        (NP (DT:[302..305] the) (JJ:[306..317] predominant)
            (NN:[318..325] product))
        (PP (IN:[326..328] of)
          (NP (DT:[329..332] the) (JJ:[333..339] pineal) (NN:[340..345] gland)))))
    (,:[345..346] ,)
    (VP (VBZ:[347..349] is)
      (VP (VBN:[350..358] involved)
        (NP-1 (-NONE-:[358..358] *))
        (PP-CLR (IN:[359..361] in)
          (NP
            (NP (DT:[362..365] the) (NN:[367..378] maintenance))
            (PP (IN:[379..381] of)
              (NP (JJ:[382..389] diurnal) (NNS:[390..397] rhythms)))))))
    (.:[397..398] .)))

;sentence 5 Span:399..539
;Nocturnal blood concentrations of melatonin have  been shown to be enhanced
;by fluvoxamine, but not by other serotonin reuptake  inhibitors.
;[433..442]:substance:"melatonin"
;[478..489]:substance:"fluvoxamine"
;[508..538]:substance:"serotonin reuptake  inhibitors"
(SENT
  (S
    (NP-SBJ-3
      (NP (JJ:[399..408] Nocturnal) (NN:[409..414] blood)
          (NNS:[415..429] concentrations))
      (PP (IN:[430..432] of)
        (NP (NN:[433..442] melatonin))))
    (VP (VBP:[443..447] have)
      (VP (VBN:[449..453] been)
        (VP (VBN:[454..459] shown)
          (S
            (NP-SBJ-3 (-NONE-:[459..459] *))
            (VP (TO:[460..462] to)
              (VP (VB:[463..465] be)
                (VP
                  (VP (VBN:[466..474] enhanced)
                    (NP-3 (-NONE-:[474..474] *))
                    (PP=2 (IN:[475..477] by)
                      (NP-LGS (NN:[478..489] fluvoxamine))))
                  (,:[489..490] ,) (CC:[491..494] but)
                  (VP (RB:[495..498] not)
                    (PP=2 (IN:[499..501] by)
                      (NP-LGS (JJ:[502..507] other)
                        
                        (NML (NN:[508..517] serotonin) (NN:[518..526] reuptake))
                        (NNS:[528..538] inhibitors)))))))))))
    (.:[538..539] .)))

;sentence 6 Span:540..813
;Because fluvoxamine is an inhibitor of several cytochrome P450 (CYP) 
;enzymes, the authors studied the biotransformation of melatonin and the
;effects  of fluvoxamine on the metabolism of melatonin in vitro using human
;liver  microsomes and recombinant human CYP isoenzymes.
;[548..559]:substance:"fluvoxamine"
;[566..575]:substance:"inhibitor"
;[587..617]:cyp450:"cytochrome P450 (CYP)  enzymes"
;[664..673]:substance:"melatonin"
;[694..705]:substance:"fluvoxamine"
;[727..736]:substance:"melatonin"
;[798..812]:cyp450:"CYP isoenzymes"
(SENT
  (S
    (SBAR-PRP (IN:[540..547] Because)
      (S
        (NP-SBJ (NN:[548..559] fluvoxamine))
        (VP (VBZ:[560..562] is)
          (NP-PRD
            (NP (DT:[563..565] an) (NN:[566..575] inhibitor))
            (PP (IN:[576..578] of)
              (NP (JJ:[579..586] several)
                
                (NML
                  (NML (NN:[587..597] cytochrome) (NN:[598..602] P450))
                  (NML (-LRB-:[603..604] -LRB-) (NN:[604..607] CYP)
                       (-RRB-:[607..608] -RRB-)))
                (NNS:[610..617] enzymes)))))))
    (,:[617..618] ,)
    (NP-SBJ (DT:[619..622] the) (NNS:[623..630] authors))
    (VP (VBD:[631..638] studied)
      (NP
        (NP
          (NP (DT:[639..642] the) (NN:[643..660] biotransformation))
          (PP (IN:[661..663] of)
            (NP (NN:[664..673] melatonin))))
        (CC:[674..677] and)
        (NP
          (NP (DT:[678..681] the) (NNS:[682..689] effects))
          (PP (IN:[691..693] of)
            (NP
              (NP (NN:[694..705] fluvoxamine))
              (PP (IN:[706..708] on)
                (NP
                  (NP (DT:[709..712] the) (NN:[713..723] metabolism))
                  (PP (IN:[724..726] of)
                    (NP (NN:[727..736] melatonin)))))))))
      (ADVP (FW:[737..739] in) (FW:[740..745] vitro))
      (S-MNR
        (NP-SBJ (-NONE-:[745..745] *))
        (VP (VBG:[746..751] using)
          (NP
            (NP (JJ:[752..757] human) (NN:[758..763] liver)
                (NNS:[765..775] microsomes))
            (CC:[776..779] and)
            (NP (JJ:[780..791] recombinant) (JJ:[792..797] human)
               (NN:[798..801] CYP) (NNS:[802..812] isoenzymes))))))
    (.:[812..813] .)))

;sentence 7 Span:814..966
;Melatonin was found to be  almost exclusively metabolized by CYP1A2 to
;6-hydroxymelatonin and  N-acetylserotonin with a minimal contribution of
;CYP2C19.
;[814..823]:substance:"Melatonin"
;[875..881]:cyp450:"CYP1A2"
;[885..903]:substance:"6-hydroxymelatonin"
;[909..926]:substance:"N-acetylserotonin"
;[958..965]:cyp450:"CYP2C19"
(SENT
  (S
    (NP-SBJ-1 (NN:[814..823] Melatonin))
    (VP (VBD:[824..827] was)
      (VP (VBN:[828..833] found)
        (S
          (NP-SBJ-1 (-NONE-:[833..833] *))
          (VP (TO:[834..836] to)
            (VP (VB:[837..839] be)
              (ADVP-MNR (RB:[841..847] almost) (RB:[848..859] exclusively))
              (VP (VBN:[860..871] metabolized)
                (NP-1 (-NONE-:[871..871] *))
                (PP (IN:[872..874] by)
                  (NP-LGS (NN:[875..881] CYP1A2)))
                (PP (TO:[882..884] to)
                  (NP (NN:[885..903] 6-hydroxymelatonin) (CC:[904..907] and)
                      (NN:[909..926] N-acetylserotonin)))
                (PP (IN:[927..931] with)
                  (NP
                    (NP (DT:[932..933] a) (JJ:[934..941] minimal)
                        (NN:[942..954] contribution))
                    (PP (IN:[955..957] of)
                      (NP (NN:[958..965] CYP2C19)))))))))))
    (.:[965..966] .)))

;sentence 8 Span:967..1144
;Both reactions were  potently inhibited by fluvoxamine, with a Ki of 0.02
;microM for the formation of  6-hydroxymelatonin and 0.05 microM for the
;formation of N-acetylserotonin.
;[1010..1021]:substance:"fluvoxamine"
;[1030..1032]:quantitative-name:"Ki"
;[1036..1040]:quantitative-value:"0.02"
;[1041..1047]:quantitative-units:"microM"
;[1070..1088]:substance:"6-hydroxymelatonin"
;[1093..1097]:quantitative-value:"0.05"
;[1098..1104]:quantitative-units:"microM"
;[1126..1143]:substance:"N-acetylserotonin"
(SENT
  (S
    (NP-SBJ-1 (DT:[967..971] Both) (NNS:[972..981] reactions))
    (VP (VBD:[982..986] were)
      (ADVP (RB:[988..996] potently))
      (VP (VBN:[997..1006] inhibited)
        (NP-1 (-NONE-:[1006..1006] *))
        (PP (IN:[1007..1009] by)
          (NP-LGS (NN:[1010..1021] fluvoxamine)))
        (,:[1021..1022] ,)
        (PP (IN:[1023..1027] with)
          (NP
            (NP (DT:[1028..1029] a) (NN:[1030..1032] Ki))
            (PP (IN:[1033..1035] of)
              (NP
                (NP
                  (NP (CD:[1036..1040] 0.02) (NN:[1041..1047] microM))
                  (PP (IN:[1048..1051] for)
                    (NP
                      (NP (DT:[1052..1055] the) (NN:[1056..1065] formation))
                      (PP (IN:[1066..1068] of)
                        (NP (NN:[1070..1088] 6-hydroxymelatonin))))))
                (CC:[1089..1092] and)
                (NP
                  (NP (CD:[1093..1097] 0.05) (NN:[1098..1104] microM))
                  (PP (IN:[1105..1108] for)
                    (NP
                      (NP (DT:[1109..1112] the) (NN:[1113..1122] formation))
                      (PP (IN:[1123..1125] of)
                        (NP (NN:[1126..1143] N-acetylserotonin))))))))))))
    (.:[1143..1144] .)))

;sentence 9 Span:1145..1271
;Other  than fluvoxamine, fluoxetine, paroxetine, citalopram, imipramine, and 
;desipramine were also tested at 2 and 20 microM.
;[1157..1168]:substance:"fluvoxamine"
;[1170..1180]:substance:"fluoxetine"
;[1182..1192]:substance:"paroxetine"
;[1194..1204]:substance:"citalopram"
;[1206..1216]:substance:"imipramine"
;[1223..1234]:substance:"desipramine"
;[1255..1256]:quantitative-value:"2"
;[1261..1263]:quantitative-value:"20"
;[1264..1270]:quantitative-units:"microM"
(SENT
  (S
    (ADJP-2 (JJ:[1145..1150] Other)
      (PP (IN:[1152..1156] than)
        (NP (NN:[1157..1168] fluvoxamine))))
    (,:[1168..1169] ,)
    (NP-SBJ-3
      (NP (NN:[1170..1180] fluoxetine) (,:[1180..1181] ,)
          (NN:[1182..1192] paroxetine) (,:[1192..1193] ,)
          (NN:[1194..1204] citalopram) (,:[1204..1205] ,)
          (NN:[1206..1216] imipramine) (,:[1216..1217] ,) (CC:[1218..1221] and)
          (NN:[1223..1234] desipramine))
      (ADJP-2 (-NONE-:[1234..1234] *ICH*)))
    (VP (VBD:[1235..1239] were)
      (ADVP (RB:[1240..1244] also))
      (VP (VBN:[1245..1251] tested)
        (NP-3 (-NONE-:[1251..1251] *))
        (PP (IN:[1252..1254] at)
          (NP
            (NP (CD:[1255..1256] 2)
              (NML-1 (-NONE-:[1256..1256] *P*)))
            (CC:[1257..1260] and)
            (NP (CD:[1261..1263] 20)
              (NML-1 (NN:[1264..1270] microM)))))))
    (.:[1270..1271] .)))

;sentence 10 Span:1272..1502
;Among the other  antidepressants, only paroxetine was able to affect the
;metabolism of melatonin  at supratherapeutic concentrations of 20 microM,
;which did not reach by far the  magnitude of the inhibitory potency of
;fluvoxamine.
;[1289..1304]:substance:"antidepressants"
;[1311..1321]:substance:"paroxetine"
;[1359..1368]:substance:"melatonin"
;[1408..1410]:quantitative-value:"20"
;[1411..1417]:quantitative-units:"microM"
;[1490..1501]:substance:"fluvoxamine"
(SENT
  (S
    (PP (IN:[1272..1277] Among)
      (NP (DT:[1278..1281] the) (JJ:[1282..1287] other)
          (NNS:[1289..1304] antidepressants)))
    (,:[1304..1305] ,)
    (NP-SBJ-3 (RB:[1306..1310] only) (NN:[1311..1321] paroxetine))
    (VP (VBD:[1322..1325] was)
      (ADJP-PRD (JJ:[1326..1330] able)
        (S
          (NP-SBJ-3 (-NONE-:[1330..1330] *))
          (VP (TO:[1331..1333] to)
            (VP (VB:[1334..1340] affect)
              (NP
                (NP (DT:[1341..1344] the) (NN:[1345..1355] metabolism))
                (PP (IN:[1356..1358] of)
                  (NP (NN:[1359..1368] melatonin))))
              (PP (IN:[1370..1372] at)
                (NP
                  (VP
                    (NP (JJ:[1373..1389] supratherapeutic)
                        (NNS:[1390..1404] concentrations))
                    (PP (IN:[1405..1407] of)
                      (NP (CD:[1408..1410] 20) (NN:[1411..1417] microM))))
                  (,:[1417..1418] ,)
                  (SBAR
                    (WHNP-1 (WDT:[1419..1424] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[1424..1424] *T*))
                      (VP (VBD:[1425..1428] did) (RB:[1429..1432] not)
                        (VP (VB:[1433..1438] reach)
                          (PP (IN:[1439..1441] by)
                            (ADVP (RB:[1442..1445] far)))
                          (NP
                            (NP (DT:[1446..1449] the)
                                (NN:[1451..1460] magnitude))
                            (PP (IN:[1461..1463] of)
                              (NP
                                (NP (DT:[1464..1467] the)
                                    (JJ:[1468..1478] inhibitory)
                                    (NN:[1479..1486] potency))
                                (PP (IN:[1487..1489] of)
                                  (NP (NN:[1490..1501] fluvoxamine)))))))))))))))))
    (.:[1501..1502] .)))

;sentence 11 Span:1503..1590
;The authors concluded that  fluvoxamine is a potent inhibitor of melatonin
;degradation.
;[1531..1542]:substance:"fluvoxamine"
;[1555..1564]:substance:"inhibitor"
;[1568..1577]:substance:"melatonin"
(SENT
  (S
    (NP-SBJ (DT:[1503..1506] The) (NNS:[1507..1514] authors))
    (VP (VBD:[1515..1524] concluded)
      (SBAR (IN:[1525..1529] that)
        (S
          (NP-SBJ (NN:[1531..1542] fluvoxamine))
          (VP (VBZ:[1543..1545] is)
            (NP-PRD
              (NP (DT:[1546..1547] a) (JJ:[1548..1554] potent)
                  (NN:[1555..1564] inhibitor))
              (PP (IN:[1565..1567] of)
                (NP (NN:[1568..1577] melatonin) (NN:[1578..1589] degradation))))))))
    (.:[1589..1590] .)))

;sentence 12 Span:1591..1766
;Because this  inhibitory action is also found in vivo, fluvoxamine might be
;used as an  enhancer of melatonin, which might offer new therapeutic
;possibilities of  fluvoxamine.
;[1646..1657]:substance:"fluvoxamine"
;[1691..1700]:substance:"melatonin"
;[1754..1765]:substance:"fluvoxamine"
(SENT
  (S
    (SBAR-PRP (IN:[1591..1598] Because)
      (S
        (NP-SBJ-3 (DT:[1599..1603] this) (JJ:[1605..1615] inhibitory)
                  (NN:[1616..1622] action))
        (VP (VBZ:[1623..1625] is)
          (ADVP (RB:[1626..1630] also))
          (VP (VBN:[1631..1636] found)
            (NP-3 (-NONE-:[1636..1636] *))
            (ADVP (FW:[1637..1639] in) (FW:[1640..1644] vivo))))))
    (,:[1644..1645] ,)
    (NP-SBJ-2 (NN:[1646..1657] fluvoxamine))
    (VP (MD:[1658..1663] might)
      (VP (VB:[1664..1666] be)
        (VP (VBN:[1667..1671] used)
          (NP-2 (-NONE-:[1671..1671] *))
          (PP-CLR (IN:[1672..1674] as)
            (NP
              (NP (DT:[1675..1677] an) (NN:[1679..1687] enhancer))
              (PP (IN:[1688..1690] of)
                (NP (NN:[1691..1700] melatonin)))))
          (,:[1700..1701] ,)
          (SBAR-ADV
            (WHNP-1 (WDT:[1702..1707] which))
            (S
              (NP-SBJ-1 (-NONE-:[1707..1707] *T*))
              (VP (MD:[1708..1713] might)
                (VP (VB:[1714..1719] offer)
                  (NP
                    (NP (JJ:[1720..1723] new) (JJ:[1724..1735] therapeutic)
                        (NNS:[1736..1749] possibilities))
                    (PP (IN:[1750..1752] of)
                      (NP (NN:[1754..1765] fluvoxamine)))))))))))
    (.:[1765..1766] .)))

;section 13 Span:1770..1815
;PMID: 11270913 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1770..1774] PMID) (::[1774..1775] :) (CD:[1776..1784] 11270913)
        (-LRB-:[1785..1786] -LSB-) (NNP:[1786..1792] PubMed)
        (HYPH:[1793..1794] -) (NN:[1795..1802] indexed) (IN:[1803..1806] for)
        (NNP:[1807..1814] MEDLINE) (-RRB-:[1814..1815] -RSB-)))
